Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 191 participants.

Also called NCT01862263

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 191 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01862263
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01862263. Randomized; double masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
Acronym
VIDA
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Insulin
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01862263
Content hash
2ff8a9e0f1a3ce20d0b9a5e91b45ad9e2f9d6219447b420f9b682b0be9ca6151